Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865548 | 0.84 | MMP1 (0.36) | MMP1MMP2MMP3MMP8 | |
| Bromide SCHEMBL31364322 | 0.81 | DNM1 (0.38) | MMP1MMP2MMP3MMP8 | |
| Water SCHEMBL28587222 | 0.81 | TSHR (0.35) | MMP1MMP2MMP3MMP8 | |
| Hydrochloric Acid SCHEMBL1428262 | 0.81 | DNM1 (0.38) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL7963143 | 0.80 | MMP1 (0.35) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL865718 | 0.79 | DNM1 (0.43) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL865701 | 0.79 | FDPS (0.36) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL520067 | 0.79 | CA12 (0.33) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL7933573 | 0.78 | MMP1 (0.34) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL10379743 | 0.77 | DNM1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | MMP1 1973/4885MMP2 1235/4885MMP3 1323/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MMP1 3446/4885MMP2 2492/4885MMP3 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.